Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
Noosa News20 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Noosa News20 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
General17 hours agoRussia launches hundreds of drones and missiles against Ukraine in fresh attack
-
Business20 hours ago2 of the best ASX ETFs to buy for a lifetime of passive income